Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Mar 25

PMID 38525009

Authors

Dong Hu

Ruyue Yang

Guidan Wang

Hao Li

Xulong Fan

Gaofeng Liang

Affiliations

Soon will be listed here.

Abstract

Adoptive T cells immunotherapy, specifically chimeric antigen receptor T cells (CAR-T), has shown promising therapeutic efficacy in the treatment of hematologic malignancies. As extensive research on CAR-T therapies has been conducted, various challenges have emerged that significantly hampered their clinical application, including tumor recurrence, CAR-T cell exhaustion, and cytokine release syndrome (CRS). To overcome the hurdles of CAR-T therapy in clinical treatment, cell-free emerging therapies based on exosomes derived from CAR-T cells have been developed as an effective and promising alternative approach. In this review, we present CAR-T cell-based therapies for the treatment of tumors, including the features and benefits of CAR-T therapies, the limitations that exist in this field, and the measures taken to overcome them. Furthermore, we discuss the notable benefits of utilizing exosomes released from CAR-T cells in tumor treatment and anticipate potential issues in clinical trials. Lastly, drawing from previous research on exosomes from CAR-T cells and the characteristics of exosomes, we propose strategies to overcome these restrictions. Additionally, the review discusses the plight in large-scale preparation of exosome and provides potential solutions for future clinical applications.

Citing Articles

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

Harnessing Tumor Cell-Derived Exosomes for Immune Rejection Management in Corneal Transplantation.

Yang J, Kang H, Liu Y, Lu S, Wu H, Zhang B Adv Sci (Weinh). 2024; 12(2):e2409207.

PMID: 39540242 PMC: 11727379. DOI: 10.1002/advs.202409207.

Nanoplatelets modified with RVG for targeted delivery of miR-375 and temozolomide to enhance gliomas therapy.

Yang T, Zhang N, Liu Y, Yang R, Wei Z, Liu F J Nanobiotechnology. 2024; 22(1):623.

PMID: 39402578 PMC: 11476726. DOI: 10.1186/s12951-024-02895-6.

Empowering brain tumor management: chimeric antigen receptor macrophage therapy.

Feng F, Shen J, Qi Q, Zhang Y, Ni S Theranostics. 2024; 14(14):5725-5742.

PMID: 39310093 PMC: 11413779. DOI: 10.7150/thno.98290.

Composition, functions, and applications of exosomal membrane proteins.

Xu F, Luo S, Lu P, Cai C, Li W, Li C Front Immunol. 2024; 15:1408415.

PMID: 39148736 PMC: 11324478. DOI: 10.3389/fimmu.2024.1408415.

References

Ma L, Dichwalkar T, Chang J, Cossette B, Garafola D, Zhang A . Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019; 365(6449):162-168. PMC: 6800571. DOI: 10.1126/science.aav8692. View

Beit-Yannai E, Tabak S, Stamer W . Physical exosome:exosome interactions. J Cell Mol Med. 2018; 22(3):2001-2006. PMC: 5824382. DOI: 10.1111/jcmm.13479. View

Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503. PMC: 6511988. DOI: 10.1038/s41591-018-0201-9. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Moriyama S, Fukata M, Yokoyama T, Ueno S, Nunomura T, Mori Y . Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy. Front Cardiovasc Med. 2022; 9:848091. PMC: 8977736. DOI: 10.3389/fcvm.2022.848091. View

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

Svoronos A, Engelman D . Pharmacokinetic modeling reveals parameters that govern tumor targeting and delivery by a pH-Low Insertion Peptide (pHLIP). Proc Natl Acad Sci U S A. 2021; 118(1). PMC: 7817199. DOI: 10.1073/pnas.2016605118. View

Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu M . CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis. J Immunother. 2017; 40(5):187-195. PMC: 5424577. DOI: 10.1097/CJI.0000000000000169. View

Fernandez Alanis E, Pinotti M, Dal Mas A, Balestra D, Cavallari N, Rogalska M . An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects. Hum Mol Genet. 2012; 21(11):2389-98. PMC: 3349419. DOI: 10.1093/hmg/dds045. View

10.

Qu Q, Fu B, Long Y, Liu Z, Tian X . Current Strategies for Promoting the Large-scale Production of Exosomes. Curr Neuropharmacol. 2023; 21(9):1964-1979. PMC: 10514529. DOI: 10.2174/1570159X21666230216095938. View

11.

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

12.

Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10):3814-3826. PMC: 5096828. DOI: 10.1172/JCI87366. View

13.

Bebelman M, Smit M, Pegtel D, Baglio S . Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018; 188:1-11. DOI: 10.1016/j.pharmthera.2018.02.013. View

14.

Feng Y, Liu X, Li X, Zhou Y, Song Z, Zhang J . Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. Oncoimmunology. 2021; 10(1):1959102. PMC: 8381848. DOI: 10.1080/2162402X.2021.1959102. View

15.

Pullan J, Confeld M, Osborn J, Kim J, Sarkar K, Mallik S . Exosomes as Drug Carriers for Cancer Therapy. Mol Pharm. 2019; 16(5):1789-1798. DOI: 10.1021/acs.molpharmaceut.9b00104. View

16.

Depil S, Duchateau P, Grupp S, Mufti G, Poirot L . 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19(3):185-199. DOI: 10.1038/s41573-019-0051-2. View

17.

Braig F, Brandt A, Goebeler M, Tony H, Kurze A, Nollau P . Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2016; 129(1):100-104. DOI: 10.1182/blood-2016-05-718395. View

18.

Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N . Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells. 2020; 9(5). PMC: 7291079. DOI: 10.3390/cells9051182. View

19.

Lu J, Wei N, Zhu S, Chen X, Gong H, Mi R . Exosomes Derived From Dendritic Cells Infected With Show Antitumoral Activity in a Mouse Model of Colorectal Cancer. Front Oncol. 2022; 12:899737. PMC: 9114749. DOI: 10.3389/fonc.2022.899737. View

20.

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View